Enhancement of Nav1.5 expression by EMPA in the dystrophic heart accords with significantly increased Scn5a gene transcript levels observed in cardiac samples from SGLT2 inhibitor-treated HF mouse models (25, 26). The gene discussed is SLC5A2; the disease is hydrops fetalis.